Compare SANA & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANA | ENOV |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 2008 |
| Metric | SANA | ENOV |
|---|---|---|
| Price | $4.46 | $26.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $7.83 | ★ $49.14 |
| AVG Volume (30 Days) | ★ 5.9M | 903.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,233,266,000.00 |
| Revenue This Year | N/A | $9.27 |
| Revenue Next Year | N/A | $4.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.57 |
| 52 Week Low | $1.26 | $25.47 |
| 52 Week High | $7.30 | $49.38 |
| Indicator | SANA | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 42.00 |
| Support Level | $4.25 | $25.52 |
| Resistance Level | $5.05 | $28.02 |
| Average True Range (ATR) | 0.49 | 1.23 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 32.35 | 30.87 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.